Prescribing Information is available here. Adverse Event reporting can be found in the footer.
Buffered, effervescent alendronate formulation supporting adherence1,2
Binosto® addresses the challenges of gastrointestinal (GI) tolerability and patient adherence to bisphosphonates, by avoiding irritation to oesophageal mucosa.1-3
Binosto® is indicated in adults for the treatment of postmenopausal osteoporosis. It reduces the risk of vertebral and hip fractures.1,2
Enhances upper GI tolerability
Avoids solid bisphosphonate irritating the oesophageal mucosa. Gastric pH levels are rapidly buffered to >3, lessening the risk of damage if reflux occurs2-5
Improved persistence with Binosto®
Fewer patients discontinued treatment due to GI adverse events with Binosto® than with conventional alendronate tablets2
Alternative option to conventional alendronate tablets: Binosto® is available as a once-a-week effervescent tablet1
A convenient formulation, improving patient adherence: Dissolves in just half a glass of plain water (120 mL)1
Low persistence with oral bisphosphonate therapy significantly hinders prevention efforts6
Bisphosphonates are recommended by NICE as first-line therapy in people at high risk of osteoporotic fracture.7 While oral bisphosphonates have broad-spectrum efficacy to reduce fragility fractures, persistence is crucial.2,8 There is a need to address the barriers to persistence, especially when long-term adherence with bisphosphonates can decrease.2,9
More than
1/5
women die within the first year of a hip fragility fracture10
Time to benefit:
12.4
months to prevent 1 non-vertebral fracture, from bisphosponate therapy, per 100 postmenopausal women with osteoporosis11
More than
2/3
of people discontinue oral bisphosphonate therapy within 1 year12
Approximately
40%
of oral bisphosphonate discontinuations may be attributed to GI side-effects (heartburn, acid reflux or ‘other’)13,14
Binosto® addresses the challenges of GI tolerability and adherence2,4,5
Significantly 81% persistence rates at 1 year with Binosto® (n=144) vs conventional alendronate tablets (n=216, 69%; p=0.009)2
Only 6% of patients discontinued Binosto® (n=144) due to preference in a real-world study, vs 13% with conventional alendronate tablets (n=217; p=0.016)2
Only 4% discontinuations due to GI-related adverse events with Binosto® (n=144) reported in real-world patients, vs 11% with conventional alendronate tablets (n=217; p=0.027)2
After taking Binosto® pH gastric pH levels are rapidly buffered to >3 and remain buffered for up to 4 hours4,5
An easy-to-take buffered, fully soluble alendronate formulation1
The recommended dose is one 70 mg effervescent tablet once weekly, taken at least 30 minutes before the first food, beverage, or medicinal product of the day.
Dissolving the tablet in water yields a buffered solution of pH 4.8 – 5.4 to avoid irritating oesophageal mucosa.
Patient Guides
Register below for an instant download of the Binosto® Patient Guide. The guide will provide more information for patients on Binosto®, how to take it, osteoporosis and tips on how to manage their condition.
References
1. Binosto® 70 mg Effervescent Tablets SmPC. Accessed: April 2026; 2. Giusti A, et al. Aging Clin Exp Res. 2021;33(9):2529-37; 3. Minisola S, et al. JBMR Plus. 2021;5(7):e10510; 4. Fuggle N, et al. Aging Clin Exp Res. 2022;34(11):2625-34; 5. Hodges LA et al. Int J Pharm. 2012;432(1-2):57-62; 6. Ashcherkin N, et al. Cleve Clin J Med. 2023;90(1):26-31; 7. NICE. TA464: Bisphosphonates for treating osteoporosis. Accessed: April 2026; 8. Bastounis A, et al. Osteoporos Int. 2022; 33(6):1223-33. 9. Fatoye F, et al. BMJ Open. 2019;14;9(4):e027049; 10. Brown JP, et al. BMC Musculoskelet Disord. 2021;22(1):105; 11. Deardorff WJ, et al. JAMA Intern Med. 2022;182(1):33-41; 12. Morley J, et al. Osteoporos Int 2020;31(3):533-45; 13. Dömötör ZR, et al. Front Endocrinol (Lausanne) 2020;11:573976; 14. Goldshtein I, et al. Adv Ther. 2016;33(8):1374-84.